LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signalling

Nature Communications

Volumn 5, Issue , 2014, Pages

  Scheffler, Julia M ^a   Sparber, Florian ^a   Tripp, Christoph H ^a   Herrmann, Caroline ^a   Humenberger, Alexandra ^b   Blitz, Johanna ^a   Romani, Nikolaus ^a   Stoitzner, Patrizia ^a   Huber, Lukas A ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ADSI Austrian Drug Screening Institute   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; LAMTOR2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; QUIZARTINIB; RAPAMYCIN; UNCLASSIFIED DRUG; FLT3 PROTEIN, MOUSE; LAMTOR2 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, MOUSE; PROTEIN; TARGET OF RAPAMYCIN KINASE;

BIOGENIC DEPOSIT; CELLS AND CELL COMPONENTS; DRUG; ENZYME ACTIVITY; GENE EXPRESSION; HOMEOSTASIS; LIGAND; RODENT;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL COMPARTMENTALIZATION; CELL EXPANSION; CELL METABOLISM; CELL PROLIFERATION; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENDOSOME; FEMALE; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL MEMBRANE; CYTOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENOTYPE; METABOLISM; TRANSGENIC MOUSE;

MAMMALIA; MUS;

ANIMALS; CELL MEMBRANE; CELL PROLIFERATION; DENDRITIC CELLS; ENDOSOMES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DELETION; GENE EXPRESSION REGULATION; GENOTYPE; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84937966696     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6138     Document Type: Article

References (44)

1. Wunderlich, W. et al. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. J. Cell Biol. 152, 765-776 (2001).
2. Teis, D., Wunderlich, W. & Huber, L. A. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev. Cell 3, 803-814 (2002).
3. Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141, 290-303 (2010).
4. Nada, S. et al. The novel lipid raft adaptor p18 controls endosome dynamics by anchoring the MEK-ERK pathway to late endosomes. EMBO J. 28, 477-489 (2009).
5. Bar-Peled, L., Schweitzer, L. D., Zoncu, R. & Sabatini, D. M. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 150, 1196-1208 (2012).
6. Magee, J. & Cygler, M. Interactions between kinase scaffold MP1/p14 and its endosomal anchoring protein p18. Biochemistry 50, 3696-3705 (2011).
7. Teis, D. & Huber, L. A. The odd couple: signal transduction and endocytosis. Cell Mol. Life Sci. 60, 2020-2033 (2003).
8. Kurzbauer, R. et al. Crystal structure of the p14/MP1 scaffolding complex: how a twin couple attaches mitogen-activated protein kinase signaling to late endosomes. Proc. Natl Acad. Sci. USA 101, 10984-10989 (2004).
9. de Araujo, M. E. et al. Stability of the endosomal scaffold LAMTOR3 depends on heterodimer assembly and proteasomal degradation. J. Biol. Chem. 288, 18228-18242 (2004).
10. Teis, D. et al. p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J. Cell Biol. 175, 861-868 (2006).
11. Bohn, G. et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nature Med. 13, 38-45 (2007).
12. Taub, N. et al. The late endosomal adaptor p14 is a macrophage host-defense factor against Salmonella infection. J. Cell Sci. 125(Pt 11): 2698-2708 ((2012).
13. Trombetta, E. S. & Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975-1028 (2005).
14. Steinman, R. M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1-22 (2012).
15. Schmid, M. A., Kingston, D., Boddupalli, S. & Manz, M. G. Instructive cytokine signals in dendritic cell lineage commitment. Immunol. Rev. 234, 32-44 (2010).
16. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
17. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118 (1994).
18. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
19. Vremec, D. et al. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur. J. Immunol. 27, 40-44 (1997).
20. McKenna, H. J. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8, 149-154 (2001).
21. Waskow, C. et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9, 676-683 (2008).
22. Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953-1962 (1996).
23. Naik, S. H. et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol. 8, 1217-1226 (2007).
24. Sathaliyawala, T. et al. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 33, 597-606 (2010).
25. Hackstein, H. et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101, 4457-4463 (2003).
26. Caton, M. L., Smith-Raska, M. R. & Reizis, B. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J. Exp. Med. 204, 1653-1664 (2007).
27. Sparber, F. et al. The late endosomal adaptor molecule p14 (LAMTOR2) represents a novel regulator of Langerhans cell homeostasis. Blood 123, 217-227 (2013).
28. Greter, M. et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031-1046 (2012).
29. Merad, M. & Manz, M. G. Dendritic cell homeostasis. Blood 113, 3418-3427 (2009).
30. Juan, T. S. et al. Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 90, 76-84 (1997).
31. Kelly, L. M. et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99, 310-318 (2002).
32. Naik, S. H. et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174, 6592-6597 (2005).
33. Zarrinkar, P. P. et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114, 2984-2992 (2009).
34. Cortes, J. E., Perl, A. E. & Smith, C. C. A phase II open -label, AC220 monotherapy efficacy study in patients with refractory/relapsed Flt3-Itd positive acute myeloid leukemia: updated interim results [abstract]. Blood (ASH Annu. Meet. Abstr.) 118, 2576 (2011).
35. Taylor, S. J., Dagger, S. A., Thien, C. B., Wikstrom, M. E. & Langdon, W. Y. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 120, 4049-4057 (2012).
36. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563-604 (2013).
37. Jewell, J. L. & Guan, K. L. Nutrient signaling to mTOR and cell growth. Trends. Biochem. Sci. 38, 233-242 (2013).
38. Pullikuth, A., McKinnon, E., Schaeffer, H. J. & Catling, A. D. The MEK1 scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho signals. Mol. Cell. Biol. 25, 5119-5133 (2005).
39. Betz, C. & Hall, M. N. Where is mTOR and what is it doing there? J. Cell. Biol. 203, 563-574 (2013).
40. Birnberg, T. et al. Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity 29, 986-997 (2008).
41. Brasel, K. et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 88, 2004-2012 (1996).
42. McClanahan, T. et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 88, 3371-3382 (1996).
43. Chklovskaia, E. et al. Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A. Blood 97, 1027-1034 (2001).
44. Laouar, Y., Welte, T., Fu, X. Y. & Flavell, R. A. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 19, 903-912 (2003).